Tramiprosate and Tau Aggregation in Alzheimer's Disease
Author Information
Author(s): Santa-Maria Ismael, Hernández Félix, Del Rio Joaquín, Moreno Francisco J, Avila Jesús
Primary Institution: Centro de Biología Molecular 'Severo Ochoa' CSIC/UAM
Hypothesis
What is the effect of Tramiprosate on tau protein aggregation in Alzheimer's disease?
Conclusion
Tramiprosate promotes tau aggregation without affecting cell viability.
Supporting Evidence
- Tramiprosate increases tau aggregation in both tau-transfected non-neuronal and neuronal cells.
- 3-APS does not affect tau's binding to microtubules.
- Cell viability remains unchanged with increasing concentrations of Tramiprosate.
Takeaway
Tramiprosate is a drug that can make tau proteins clump together, which is important for understanding Alzheimer's disease.
Methodology
The study tested the effects of Tramiprosate on tau aggregation in both non-neuronal and neuronal cells using various assays including immunofluorescence and Western blot.
Limitations
The study primarily focused on in vitro models, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website